News Daily News Who Benefits Most From Semaglutide and How Long Will That Take? Shelley Wood December 19, 2023
News Daily News Lp(a) Appears Tied to Myocardial Fibrosis: Observational Data Yael L. Maxwell December 13, 2023
News Conference News AHA 2023 POP-HT: Physician-Guided Self-Monitoring Improves BP After Hypertensive Pregnancy L.A. McKeown November 13, 2023
News Conference News HFSA 2023 Semaglutide Works Across LVEF Range: STEP-HFpEF Analysis Todd Neale October 11, 2023
News Conference News ESC 2023 ESC Focused Update on HF Synthesizes New Trial Data for Practical Use L.A. McKeown September 01, 2023
News Conference News ESC 2023 New ESC Guidelines for CVD in Patients With Diabetes Cover Wide Ground Caitlin E. Cox August 30, 2023
News ESC 2023 Qiliqiangxin, a Traditional Chinese Medication, Cuts CV Events in HF: QUEST Michael O'Riordan August 27, 2023
News Daily News Global Numbers Paint Grim Picture of GDMT Uptake, Costs, and HF Outcomes Michael O'Riordan June 23, 2023
News Daily News New Expert Consensus Papers Aim to Boost Management, Outcomes in HFpEF L.A. McKeown April 19, 2023
News Daily News Borderline Cost-effectiveness for SGLT2 Inhibitors in HFpEF Todd Neale March 15, 2023
News Conference News ACC 2023 IMPLEMENT-HF: ‘Virtual’ Stewardship May Help Optimize GDMT in HFrEF L.A. McKeown March 14, 2023
News Conference News ACC 2023 Viability Testing Fails to Find HF Patients Who’d Benefit From PCI in REVIVED-BCIS2 Michael O'Riordan March 09, 2023
News Daily News Cardiac Biomarkers May Help Refine HF Risk Stratification, Progression L.A. McKeown February 17, 2023
News Daily News HFrEF’s Financial Burden May Get Relief From Inflation Reduction Act L.A. McKeown January 13, 2023
News Daily News Semaglutide Effective for Weight Loss in Adolescents: STEP TEENS Michael O'Riordan December 30, 2022
News Daily News Anatomic Disease After PCI Linked With Worse Outcomes: VA CART Michael O'Riordan December 22, 2022
News Daily News FDA Advisors Recommend Against Approval of Omecamtiv Mecarbil Michael O'Riordan December 14, 2022
News Daily News Analysis Cements Benefits of SGLT2 Inhibitors in HF, but Diabetes Matters for Deaths Michael O'Riordan December 08, 2022
News Daily News Sky-high Cost of SGLT2i and GLP1 Agonists Deter First-line Use L.A. McKeown October 05, 2022